$31m in new funds to help Cebix progress novel peripheral neuropathy candidate

San Diego-based Cebix has closed a $30.9 million Series B venture capital financing round to fund Phase IIb development for the company's C-peptide replacement therapy Ersatta, which may become the first disease-modifying treatment for peripheral neuropathy in type 1 diabetes patients.

Several companies have sought regulatory approvals for drugs that reduce the pain of diabetic peripheral neuropathy, rather than develop therapies...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Sumitomo Parkinson’s Filing A Pivotal Moment For Japan’s iPSC Ambitions

07 Aug 2025

• By Lisa Takagi

Sumitomo Pharma's iPSC therapy for Parkinson's has been filed for approval in Japan after showing safety and efficacy in a Phase I/II trial and may become one of the first such therapies to reach the market in the country, which has invested heavily in the modality.

HHS mRNA Vaccine Wind-Down Has Limited Impact (And One Contract Isn’t Even mRNA)

06 Aug 2025

• By Alaric DeArment

The news will have a big impact on pandemic preparedness but less immediate financial impact. Tiba Biotech was even “caught off guard” by its inclusion in the department’s culling of mRNA vaccine projects under BARDA, as its project was neither a vaccine nor mRNA-based.